AORTICLAB is an innovative start-up that offers high-tech cutting-edge solutions in the treatment of AORTIC STENOSIS, which affects millions of people in the world. Even today, many of them are suffering from severe aortic stenosis and remain unteated. The AORTICLAB mission is to respond to the needs of patients suffering from severe aortic stenosis who have had no hope of cure to date because of their age or poor health conditions. In addition, we enable safer TAVI procedures that protect patients from cerebral (stroke) and peripheral risks, raising the quality and efficacy standards of aortic stenosis treatment. A beating heart carries memories, affections, emotions and little–big hopes for the future. Those who suffer from severe aortic stenosis, young and old alike, may have a shorter future expectation for them, but no less intense and no less deserving of hope. The profound value of each person’s story, the immense wealth of emotions that our loved ones reserve for us and sheer respect for all aspects of life are the inspiration that has driven us since day one. It is why our research and innovation path, state-of-the-art technology and protection walk hand in hand. The effectiveness of our solutions and the achievement of lower risk for patient and clinical staff are actually two parallel paths with a common endpoint: patients’ safety and quality of life. Pursuing this objective has brought us to the launch of products for safer and less invasive treatment of aortic stenosis, offering sustainable heart interventional solutions. We are a young business, founded on extensive experience. We are a cohesive team, driven by passion and by a pioneering approach. FLOwer (Embolic Protection Device) and GEMINI (Transcatheter Treatment) are currently under development. Commercial release for FLOwer is expected in 2023 in selected European countries.